Search This Blog

Wednesday, May 20, 2026

Dyne begins FDA-aligned Phase 3 trial of z-rostudirsen in Duchenne

 

Dyne Therapeutics begins FDA-aligned Phase 3 FORZETTO trial of z-rostudirsen in Duchenne muscular dystrophy ahead of BLA filing

  • FORZETTO study is a confirmatory Phase 3 trial supporting planned U.S. accelerated approval of z-rostudirsen.
  • First clinical site in the FORZETTO trial is now open for enrollment in Duchenne muscular dystrophy.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)